[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-survivors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-survivors":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,57,90,113,147,183,212,240,263,290,319,348,381,407,440,465,487,513,536,557,583],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100605376","sbu-reset-relaxation-stress-reduction-and-epigenetics-trial-in-cancer-survivors-100605376",false,"NCT07161713","SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors","Pilot Study of a Social\u002FBehavioral Intervention on Cancer Survivors, Evaluating the Effect of Mind Body Interventions on Patient Reported Outcomes, Inflammation and Epigenetics.","RESET","Inclusion Criteria:\n\n* Adults over 18 years old\n* Primary diagnosis: Lung Cancer, Colon Cancer and Non-Hodgkin's lymphoma (NHL)\n* Six months post cancer-directed treatment (chemotherapy, targeted and immunotherapy). Patients with active disease (e.g. metastatic colorectal cancer) who are not receiving any cancer-directed treatment are eligible.\n* Able to provide a saliva sample\n* Gives informed consent and agrees to be randomly assigned\n* Able to complete the questionnaire(s) in English.\n\nExclusion Criteria:\n\n* Adults with primary anal and\u002For primary rectal cancer.\n* Adult cancer survivors who are currently on an active treatment regimen.\n* Oral or any pathological conditions that can limit the ability to produce saliva.\n* Unable to participate in full length study period and follow up thereafter.\n* Is pregnant or plan to become pregnant during the study period.\n* Currently practicing yoga or SMART\n* Those on corticosteroid therapy.\n* Documented fall or syncope within the last 6 months","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cancer survivors can experience health issues that cause chronic illness and lower quality of life. Yoga is a well-known holistic approach to health and overall well-being. Mindfulness has many benefits, including improved focus and less stress. This study aims to evaluate if yoga and\u002For mindfulness has a positive effect on cancer survivors social, emotional and physical well-being as well as their epigenetics. Epigenetics is how the environment can effect your genes; not by changing our DNA, but by turning genes on or off.",[27,28,29],"Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)","Cancer Survivors","Cancer Survivorship",[31,32,33,34,35,36,37,38,39,40,41,42,43],"stony brook","survivor","yoga","mindfulness-based stress reduction","holistic","stress management","cancer survivor","long island","mindfulness","cancer","EORTC","questionnaires","surveys","RECRUITING","2026-06-26",{"date":47,"type":48},"2026-06-30","ACTUAL",{"date":50,"type":48},"2025-09-17",{"date":52,"type":21},"2027-09-30",{"name":54,"class":55},"Barbara Nemesure","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":65,"minAge":18,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":69,"briefSummary":70,"conditions":71,"keywords":77,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":56},"100645009","empowerher-hybrid-digital-intervention-for-breast-cancer-survivors-100645009","NCT07676591","EmpowerHer: Hybrid Digital Intervention for Breast Cancer Survivors","EmpowerHer: Protocol for a Multicentre Randomized Controlled Trial Evaluating a Hybrid Digital Exercise and Education Intervention for Breast Cancer Survivors Across Five European Countries","EmpowerHer","Inclusion Criteria:\n\n* Women aged 18-65 years.\n* History of breast cancer.\n* Completed primary treatment (surgery, chemotherapy, and\u002For radiotherapy; adjuvant hormone therapy is permitted).\n* No evidence of active or metastatic disease at enrolment.\n* Able to provide informed consent and communicate in the local language.\n* Own and are able to use a smartphone.\n* Willing to engage in the exercise program.\n\nExclusion Criteria:\n\n* Cognitive impairment preventing safe participation or questionnaire completion.\n* Uncontrolled medical conditions that contraindicate exercise (e.g., unstable cardiac disease).\n* Concurrently enrolled in another structured exercise or survivorship study.\n* Pregnant or breastfeeding.","FEMALE","65 Years",{"count":68,"type":21},147,[24],"The goal of this clinical trial is to learn if a 12-week hybrid exercise and education program (EmpowerHer) works to improve health-related quality of life in breast cancer survivors aged 35 to 65.\n\nThe main questions it aims to answer are:\n\n* Does the EmpowerHer program improve the everyday quality of life of participants?\n* Does the program lower fatigue, anxiety, and depression while raising physical fitness?\n\nResearchers will compare the EmpowerHer program to usual medical care to see if the program works better to help survivors recover.\n\nParticipants will:\n\n* Use a mobile application at home at least twice a week for structured exercise.\n* Read short educational modules on the mobile application about health after cancer.\n* Attend weekly in-person motivational group sessions with a program facilitator.\n* Complete health and physical tests at the start, at 12 weeks, and 3 months later.",[72,28,73,74,75,76],"Breast Cancer","Quality of Life","Exercise Therapy","Social Support","Mobile Applications",[78,74,79,76,75,80,73],"Breast Cancer Survivors","Digital Health","Multicentre Randomized Controlled Trial","NOT_YET_RECRUITING","2026-06-23",{"date":47,"type":48},{"date":85,"type":21},"2027-07-01",{"date":87,"type":21},"2028-06-30",{"name":89,"class":55},"University of Valencia",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":56},"100580237","evaluating-laser-photobiomodulation-for-the-treatment-of-neuropathic-pain-in-chemotherapy-induced-peripheral-neuropathy-in-cancer-patients-100580237","NCT06834685","Evaluating Laser Photobiomodulation for the Treatment of Neuropathic Pain in Chemotherapy-induced Peripheral Neuropathy in Cancer Patients","Evaluating Laser Photobiomodulation for the Treatment of Neuropathic Pain in Chemotherapy-induced Peripheral Neuropathy: a Randomized, Non-comparative, Placebo-controlled, Single-blinded, Phase II Clinical Trial in Cancer Patients","NEUROdoux","Inclusion Criteria:\n\n* Male or female aged 18 years minimum;\n* Patient treated at the Montpellier Cancer Institute for a cancer (whatever the location) requiring a chemotherapy;\n* Patient with significant NP defined as a score of 4 at the clinician-rated DN4 ;\n* Patient with a NP for at least 3 months after the end of an adjuvant or neo-adjuvant chemotherapy;\n* Women of childbearing potential must have a pregnancy urinary test within a maximum of 7 days before starting the study treatment. A negative result must be documented before study treatment is started. Women without reproductive potential are postmenopausal women or women who have undergone permanent sterilisation (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy);\n* Effective contraception for women of childbearing age\n* Patient having signed informed consent prior to any study procedure;\n* Patient affiliated to a French social protection system;\n* Patient sufficiently fluent in French to complete questionnaires, as the investigator clinical discretion.\n\nExclusion Criteria:\n\n* Patient unable to come twice a week to the Montpellier Cancer Institute;\n* Patient unable to sit for a 30-minutes period;\n* Patient with an open wound or ulcer on the treatment area;\n* Patient whose diagnosis of peripheral neuropathy is due to another cause (n.b., diabetes without neuropathy will not be a specific exclusion);\n* Patient with uncontrolled psychiatric illness or neurocognitive impairment that may interfere with assessments, as the investigator clinical discretion;\n* Patient whose estimated life expectancy is less than 3 months, as estimated by a clinical investigator;\n* Patient using another concurrent non-pharmacological intervention or complementary therapy for neuropathy during the study;\n* Patient who has been treated with CAPSAISINE during the previous 3 months;\n* Patient with pacemaker;\n* Epileptic patient;\n* Patient with photosensitive medications, or any medical condition causing sensitivity to light (n.b., Lupus);\n* Pregnant and\u002For breastfeeding woman;\n* Patient with primary tumor and\u002For metastases in areas to be treated by BPM (i.e., hands and\u002For feet);\n* Patient with pre-existing eye disease (such as maculopathy, glaucoma, cataract and retinal lesions), or a history of family eye diseases;\n* Patient who has been already been treated with photobiomodulation on the area of interest.\n* Participation in another concomitant clinical study with neuropathic pain or chemo-induced peripheral neuropathy as the primary endpoint.\n* Presence of a tattoo on the area to be treated.",{"count":99,"type":21},70,[24],"Chemotherapy-induced peripheral neuropathy (CIPN) (including taxanes, platinum, al pervenche from Madagascar alkaloids...), is a frequent secondary effect of treatments: 68% at 1-month post-chemotherapy, 60% at 3 months and 30% after 6 months. Symptoms associated with CIPN are usually symmetric and bilateral (typical distribution in \"gloves and socks\") inducing sensory alterations, paresthesias, dysesthesias, numbness and pain. Neuropathic Pain (NP) is an important characteristic of CIPN, affects 25-80% of patients with CIPN, and reduces quality of life (e.g., concomitant psychological distress, risks of falls, risks of neurocognitive impairments, and sleep disorders).\n\nIn severe cases, it is even necessary to delay and\u002For reduce the dose of chemotherapy. The benefit of drug interventions on NP remains limited. To date, there are no proven preventive strategies and few evidence-based treatment options for CIPN. Also, the use of complementary or non-pharmacological interventions are common, including photobiomodulation (PBM).\n\nPBM is the therapeutic use of non-ionizing laser light for its anti-inflammatory and regenerative effects. Its use is currently recommended only for the prevention of oral mucositis related to cancer treatments. Recent preliminary clinical evidence suggests that PBM may be beneficial to established CIPN, with safety and improvement beyond the intervention. However, to date, clinical trials are rare, have methodological weaknesses, and\u002For focus on global CIPN. The overall objectives of the study are therefore to assess the effectiveness, feasibility and safety of the PBM for treating NP in the CIPN.",[28,103],"Peripheral Neuropathic Pain","2026-06-02",{"date":106,"type":48},"2026-06-04",{"date":108,"type":48},"2025-10-07",{"date":110,"type":21},"2028-12",{"name":112,"class":55},"Institut du Cancer de Montpellier - Val d'Aurelle",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":56},"100594654","virtual-exercise-training-and-its-impact-on-bone-compartments-in-adult-survivors-of-childhood-cancer-100594654","NCT07022262","Virtual Exercise Training and Its Impact on Bone Compartments in Adult Survivors of Childhood Cancer","3D-BONE: Virtual Exercise Training and Its Impact on Cortical and Trabecular Bone Compartments in Adult Survivors of Childhood Cancer: a Peripheral Quantitative Computed Tomography (pQCT) Study","3D-BONE","Inclusion Criteria:\n\n* Prior diagnosis of pediatric cancer and history of receiving treatment (radiation therapy and\u002For chemotherapy).\n* 18-55 years of age at recruitment\n\nExclusion Criteria:\n\n* Participation in another research study simultaneously.\n* Not currently receiving cancer treatment.\n* Previous diagnosed anorexia\u002Fbulimia, known pregnancy, known alcohol or drug abuse.\n* Requiring chronic oral glucocorticoid therapy.\n* Having an injury that may affect daily life activities and can be aggravated by exercise.","55 Years",{"count":123,"type":21},116,[24],"Childhood cancer is a rare disease but a significant cause of death in children and adolescents. The incidence of childhood cancer is 1case per 300 cases of adult cancer, but surviving to it has important sequels. Endocrine dysfunction represents one of the most common issues in paediatric cancer survivors and impairs bone mineral density later in life. Some forms of exercise have been recommended to preserve bone health in healthy adults; however, its effect has not been properly studied yet in adult survivors of paediatric cancer using cutting-edge technologies, such as peripheral quantitative computed tomography (pQCT). As general aim, the 3D-BONE study will assess for the first time the effect of a live and online exercise programme on bone parameters and bone metabolism in adult survivors of paediatric cancer. This multicenter randomized controlled trial will be performed in three Andalusian provinces (Granada, Cordoba and Almeria). A minimum of 116 adult survivors of paediatric cancer aged 18 to 55 years will be recruited following the inclusion and exclusion criteria. They will be randomized (based on sex and age) into an INTERVENTION (n=58) or CONTROL group (n=58). The intervention group will receive a 6-month live and online exercise program based on progressive resistance and impact loading training that will be delivered by qualified professionals using a telehealth mobile app (3D-BONE app). Moreover, behaviour change techniques will be implemented in order to increase motivation and adherence to the program. This group will also receive diet counselling on calcium and vitamin so the difference between the groups is the exercise programme. Participants will be assessed before and after the intervention at the facilities of the Sport and Health University Research Institute (iMUDS) of the University of Granada. An in-depth analysis of bone parameters will be carried out using cutting-edge technologies, such as the pQCT (to analyse cortical and trabecular bone in 3 dimensions), dual-energy X-ray absorptiometry (DXA), hip and lumbar spine geometry outcomes. Moreover, a complete blood count will be obtained and markers of bone metabolism will be measured (B-CTX, PINP), including novel markers such as sclerostin and irisin which have recently been linked to human bone. Data will also be collected in anthropometry and body composition to obtain cardiovascular risk factors, sarcopenia and physiologic frailty risk factors, mental health, health-related quality of life and objective measures of physical activity and fitness. This will ensure obtaining novel, precise and strong data in this population.",[28],[128,129,130,131,132,133,134,135,136,137],"cancer survivors","childhood cancer","exercise","bone health","physical fitness","sarcopenia","physiological frailty","mental health","health-related quality of life","pQCT","2026-04-29",{"date":140,"type":48},"2026-05-06",{"date":142,"type":21},"2026-05",{"date":144,"type":21},"2028-08",{"name":146,"class":55},"Universidad de Granada",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":168,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100636151","a-smart-phone-application-to-improve-adoption-of-the-2024-kidney-disease-improving-global-outcomes-kdigo-chronic-kidney-disease-ckd-guidelines-100636151","NCT07561957","A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines","A Smart Phone Application to Improve Adoption of the 2024 KDIGO CKD Guidelines","Inclusion Criteria:\n\n* Adults aged ≥16 years.\n* Diagnosed with CKD stages 1-5.\n* Owns a smartphone and is capable of using mobile applications.\n* Provides informed consent.\n\nExclusion Criteria:\n\n* Inability to provide informed consent due to a neurocognitive impairment.\n* Age 30 years or older\n\nThe study will be conducted in the already established SJH Young Adult Clinic, with anticipated expansion coinciding with the co-location Children's Health Ireland (CHI) on site.","16 Years","30 Years",{"count":157,"type":21},80,[24],"The goal of this study is to establish whether use of a digital intervention can improve adherence and alignment with the Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) 2024 Guidelines.\n\nA subset of the study will focus on whether the intervention improves outcomes for young adults living with CKD, in the context of the imminent co-location of Children's Health Ireland on the St. James's Hospital campus.\n\nYoung adults with CKD transitioning to adult services are recognised as a high-risk and vulnerable cohort, with many individuals unaware of increased cardiovascular risk and mortality¹². In response, and in the context of the co-location of Children's Health Ireland on the St. James's Hospital site, a young adult nephrology clinic has been established.\n\nThe KDIGO CKD 2024 Guidelines identify transition as a period of increased risk and include recommendations regarding cardiovascular risk factor targets and the use of therapies known to delay CKD progression³.\n\nElectronic communication is a preferred method for accessing health information among many young adults⁴⁵ and aligns with Sláintecare digital health strategies⁶. A recently established, award-winning St. James's Hospital renal smartphone application is currently used by over 3,000 individuals living with CKD.\n\nThe study aims to determine whether use of the application improves adherence to KDIGO guideline recommendations, with the objective of delaying CKD progression and associated complications. The application will support optimisation of care by signposting opportunities for evidence-based interventions (e.g., SGLT2 inhibitors, renin-angiotensin system inhibition) to healthcare providers. The application will also provide participants with tailored recommendations, reminders, educational materials, and collection of patient-reported outcome measures.\n\nDue to the diverse population and range of specialties at St. James's Hospital, the young adult clinic serves distinct subgroups, including individuals with sickle cell anaemia and survivors of cancer and haematological malignancies. These populations will be examined in the context of KDIGO guideline implementation, contributing to a limited international evidence base.\n\nThis research evaluates an intervention designed to improve care for adults living with chronic kidney disease.",[161,162,163,164,165,166,167,28],"Chronic Kidney Disease","Proteinuria","Blood Pressure Control","Congenital Anomalies of the Kidneys and Urinary Tract","Nephrotic Syndrome","Sickle-Cell Nephropathy","Tuberous Sclerosis Complex",[169,170,171,172],"Digital Interventions","Kidney Disease","Paediatric Nephrology","Transitional Nephrology","2026-04-24",{"date":175,"type":48},"2026-05-01",{"date":177,"type":48},"2026-01-14",{"date":179,"type":21},"2027-06-01",{"name":181,"class":55},"St. James's Hospital, Ireland",2,{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":197,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":56},"100631399","fighting-the-fear-of-cancer-recurrence-in-cancer-survivors-a-pilot-study-on-the-effectiveness-of-metacognitive-therapy-100631399","NCT07500168","Fighting the Fear of Cancer Recurrence in Cancer Survivors: A Pilot Study on the Effectiveness of Metacognitive Therapy","MCT-FCR","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Patients with cancer classified as stage I, II, or III according to the TNM staging system who have completed primary cancer treatment.\n3. Ability to understand and read Chinese, with no significant cognitive impairment.\n4. A score of 13 or higher on a validated measure of fear of cancer recurrence.\n\nExclusion Criteria:\n\n1. Individuals with severe psychiatric disorders.\n2. Individuals who have difficulty communicating in Mandarin. -",{"count":191,"type":21},120,[24],"This study aims to evaluate the effectiveness of metacognitive therapy (MCT) in reducing fear of cancer recurrence (FCR) among cancer survivors.\n\nWith advances in cancer treatment, more patients are surviving cancer. However, many survivors continue to experience fear of cancer recurrence, which can affect their emotional well-being, quality of life, and ability to return to normal daily activities.\n\nIn this study, participants will receive a structured psychological intervention adapted from the ConquerFear program. This program has been modified to better fit local cultural needs.\n\nParticipants will be randomly assigned to receive either metacognitive therapy or relaxation therapy.\n\nThe study will compare the effects of these interventions on reducing fear of cancer recurrence, as well as their impact on emotional distress and quality of life.\n\nThe results of this study may help develop effective psychological treatments to support cancer survivors in managing fear of recurrence and improving overall well-being.",[195,28,196],"Fear of Cancer Recurrence","Psychological Distress",[195,28,198,199,200,201,202,73],"Psycho-oncology","ConquerFear","Randomized Controlled Trial","Anxiety","Depression","2026-03-24",{"date":205,"type":48},"2026-03-30",{"date":207,"type":21},"2026-04",{"date":209,"type":21},"2028-12-31",{"name":211,"class":55},"Koo Foundation Sun Yat-Sen Cancer Center",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":65,"minAge":18,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":226,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":56},"100628350","plyometric-strength-endurance-exercise-in-breast-cancer-100628350","NCT07460492","Plyometric Strength-Endurance Exercise in Breast Cancer","Therapeutic Plyometric-Based Strength-Endurance Exercise Program for Breast Cancer Patients and Survivors to Improve Quality of Life and Physical and Mental Function","Inclusion Criteria:\n\n* Women aged 18 years or older.\n* Prior diagnosis of breast cancer.\n* History of mastectomy, including unilateral procedures, total breast surgery, or breast-conserving surgery.\n* Completion of postoperative chemotherapy or radiotherapy, when indicated.\n* Absence of contraindications for physiotherapy or therapeutic exercise.\n* Willingness to voluntarily participate in the study.\n* Ability to understand and sign the informed consent form.\n* Availability to participate in the training program for the entire intervention period (approximately 12 weeks).\n\nExclusion Criteria\n\n* Participants will be excluded if any of the following conditions are present:\n* Active metastasis to other organs or tissues (e.g., liver, kidney, lung, brain) or stage IV cancer that prevents safe participation in the therapeutic exercise program.\n* Current diagnosis of cardiovascular, respiratory, neuromuscular, or musculoskeletal diseases that contraindicate physical exercise or impair safe completion of the program.\n* Major surgery within the previous 6 months without medical clearance to resume physical activity.\n* Cognitive impairment or mental health conditions that limit comprehension of instructions or safe engagement in the intervention.\n* Current pregnancy.\n* Lack of medical clearance for moderate-to-vigorous physical activity (as indicated by a medical certificate specifying the duration of the restriction and the conditions under which exercise may be resumed).",{"count":220,"type":21},51,[24],"This study aims to compare an adapted plyometric strength-endurance exercise program with conventional strength training in women who are breast cancer survivors or currently undergoing treatment and who participate in provincial support associations. The goal is to determine whether a targeted plyometric intervention can provide additional benefits in physical and mental health outcomes.\n\nUsing a cluster-randomized clinical trial design, the study will assess indicators such as functional capacity, muscle strength, fatigue levels, symptoms related to lymphedema, and overall quality of life. The findings are expected to contribute to a better understanding of how structured exercise programs can support recovery, physical function, and well-being in women affected by breast cancer.",[224,225,28],"Neoplams","Patients",[200,227,228,229,230,135],"Cluster Analysis","quality of life","physical functional performance","functional status","2026-03-10",{"date":233,"type":48},"2026-03-13",{"date":235,"type":21},"2026-04-20",{"date":237,"type":21},"2027-12-31",{"name":239,"class":55},"University of Vigo",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":17,"minAge":247,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":56},"100585602","assessment-of-sleep-quality-in-patients-treated-for-cancer-between-15-and-24-years-of-age-100585602","NCT06904495","Assessment of Sleep Quality in Patients Treated for Cancer Between 15 and 24 Years of Age","SOM'AJA","Inclusion Criteria:\n\n* Patient treated for a cancer\n* Patient aged between 15 and 24 years old at the time of the diagnosis\n* Patients whom intensive treatment ended at least 3 months ago\n* Patient followed in a PACAAURA cancerology center\n* Life expectancy ≥ 6 months\n* Karnosky index \\> 60%\n* Patient who agrees to participate in the program and benefits from social security\n* Patient able to understand, speak and read French.\n* No major cognitive impairment (assessed by the patient's referees)\n* No sensory disability\n\nExclusion Criteria:\n\n* Patient unable to use informatic tools\n* Known superior cognitive function disorders\n* Progressive psychiatric pathology\n* Drug user or alcohol abuse","15 Years","24 Years",{"count":250,"type":21},400,[24],"Medical professionals now take into account the specificities of the care and support of Adolescents and Young Adults (AYAs). Cancer aftermaths in patients diagnosed during the AYA period are also known: the consequences of chemotherapy and radiotherapy treatments on a growing organism, the difficulty of some follow-ups, the longevity, and the delayed occurrence of certain complications.\n\nIn the general population, sleep disorders affect 40% of adolescents. About 30% of pediatric cancer survivors experience fatigue they attribute to their cancer, even years after the end of their treatment. The sleep quality of patients treated for cancer when they were AYAs, and the eventual care of sleeping disorders, are poorly studied. The investigators suppose that the oncologic treatment during this particular life stage, when sleeping disorders are already present and multifactorial, could have long-term impacts on sleep. The investigators offer to evaluate, through a questionnaire filled out by patients treated for cancer in the AYA period, the frequency of moderate to severe insomnia.",[28],"2026-02-26",{"date":256,"type":48},"2026-02-27",{"date":258,"type":48},"2025-04-15",{"date":260,"type":21},"2026-05-05",{"name":262,"class":55},"Centre Hospitalier Universitaire de Nice",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":271,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":56},"100594771","improving-sleep-fatigue-activity--quality-of-life-in-cancer-survivors-via-a-transdiagnostic-intervention-100594771","NCT07023783","Improving Sleep, Fatigue, Activity & Quality of Life in Cancer Survivors Via a Transdiagnostic Intervention","Using a Transdiagnostic Sleep Health Intervention Approach to Improve Sleep Quality and Subsequent Daytime Fatigue, Physical Activity, and Quality of Life in Cancer Survivors","SLEEP-CARE","Inclusion Criteria:\n\n* ≥18 years old\n* ≤7 on RU-SATED questionnaire\n* ≥6 months removed from primary cancer treatment\n* able to speak\u002Fread English\n* can sign informed consent\n* have internet access via smartphone or computer\n\nExclusion Criteria:\n\n* ≥15 on Patent Health Questionnaire 8\n* ≥10 on Generalized Anxiety Disorder-7\n* self-reported current or recent history (≤2 years) of drug or alcohol abuse\n* history of nervous system disorder \\[e.g., stroke, Parkinson's disease, multiple sclerosis\\]\n* severe mental illness such as schizophrenia or bipolar disorder\n* current or recent history (≤5 years) of shift work\n* currently receiving a sleep intervention",true,{"count":273,"type":21},12,[24],"Poor sleep affects over half of U.S. cancer survivors, contributing to daytime fatigue, reduced physical activity, and diminished quality of life. Traditional sleep treatments often target diagnosed disorders, leaving many survivors with subclinical sleep issues underserved. Sleep health-a broader concept encompassing sleep regularity, satisfaction, alertness, timing, efficiency, and duration (RU-SATED)-offers a more inclusive framework for intervention. The TSHI is a modular, skills-based program designed to improve these dimensions of sleep health. Delivered via six weekly one-on-one Zoom sessions, TSHI emphasizes behavioral strategies like sleep hygiene, relaxation, and energy management.\n\nThis six-week, single-group quasi-experimental pilot study will enroll 10 cancer survivors to assess the feasibility, acceptability, and preliminary effectiveness of TSHI. Researchers will evaluate changes in sleep health, fatigue, physical activity, and quality of life using surveys, interviews, and ActiGraph data. By targeting sleep as a modifiable health behavior, this study aims to lay the groundwork for scalable interventions that enhance recovery and well-being in cancer survivors.",[28],[278,279,280],"Sleep Health","Physical Activity","Cancer Related Fatigue","2026-02-04",{"date":283,"type":48},"2026-02-06",{"date":285,"type":21},"2026-08",{"date":287,"type":21},"2026-10",{"name":289,"class":55},"University of Oklahoma",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":4},"100620838","a-study-on-the-efficacy-of-the-metaverse-lifestyle-health-education-model-based-on-the-transtheoretical-model-for-improving-quality-of-life-and-modifying-lifestyle-in-colorectal-cancer-survivors-100620838","NCT07362823","A Study on the Efficacy of the Metaverse Lifestyle Health Education Model Based on the Transtheoretical Model for Improving Quality of Life and Modifying Lifestyle in Colorectal Cancer Survivors","Inclusion Criteria:\n\n1. Patients with first diagnosed colorectal cancer who have undergone radical surgical treatment\n2. Aged ≥18 years old and non-pregnant\n3. Have basic communication, reading and comprehension abilities, and can proficiently use smartphones and WeChat\n4. Voluntarily sign the informed consent form and promise to cooperate in completing all interventions and follow-up assessments\n\nExclusion Criteria:\n\n1. Patients with other types of malignant tumors\n2. Patients with incompletely resected tumors or distant metastases\n3. Patients with dysfunction of important organs such as heart, liver and kidney, or with unstable\u002Frapidly deteriorating conditions\n4. Patients with severe cognitive impairment who cannot communicate normally and cooperate with the intervention",{"count":297,"type":21},174,[24],"Colorectal cancer is a globally prevalent malignant tumor. Postoperative patients often face physical discomfort, psychological stress, and lack of healthy lifestyles. However, traditional health education models have limitations such as insufficient targeting and poor interactivity, making it difficult to meet their needs for full-cycle health management. This study is a multicenter randomized controlled trial, which plans to enroll 174 patients aged 18 years and above who have undergone radical resection for colorectal cancer, and randomly divide them into an experimental group and a control group at a ratio of 1:1. The experimental group will receive Transtheoretical Model (TTM)-based metaverse lifestyle health education (including phased course learning, metaverse immersive interaction, and WeChat group check-in supervision) with an intervention cycle of 1 months and follow-up until 3 months after the intervention; the control group will only receive routine paper-based education and outpatient follow-up. The study aims to verify the improvement effect of this metaverse intervention model on the quality of life and healthy lifestyle of colorectal cancer survivors, and explore its role in improving patients' self-efficacy, so as to provide empirical evidence for optimizing long-term health management programs for cancer survivors.",[301,28],"Colorectal Neoplasms",[301,28,303,304,305,306,73,307,308,309],"Transtheoretical Model (TTM)","Metaverse","Lifestyle Intervention","Health Education","Self-Efficacy","Health Behavior","Multicenter Randomized Controlled Trial","2026-01-26",{"date":312,"type":48},"2026-01-28",{"date":314,"type":21},"2026-01-20",{"date":316,"type":21},"2026-09-30",{"name":318,"class":55},"Qu Shen",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":22,"phases":328,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":56},"100453045","targeted-telerehabilitation-following-curative-intent-therapy-of-lung-cancer-100453045","NCT05179408","Targeted Telerehabilitation Following Curative Intent Therapy of Lung Cancer","Telerehabilitation for Veteran Lung Cancer Survivors Following Curative Intent Therapy","Inclusion Criteria:\n\n* Adult Veterans with a history of stage I-III A\u002FB lung cancer, and\n* Completed curative intent therapy (i.e., lung cancer resection surgery, definitive radiation, or concurrent chemoradiation) within 1-6 months\n\nExclusion Criteria:\n\n* Adult Veterans with any comorbid conditions that preclude participation in exercise and telerehabilitation:\n* Orthopedic conditions (e.g., bilateral below-knee amputation), or\n* Severe cardiopulmonary disease (e.g., unstable arrhythmias including ventricular tachycardia, heart failure with systolic ejection fraction \\\u003C 25%, chronic hypoxemia needing \\> 5 L\u002Fmin oxygen supplementation at rest), or\n* Inability to follow directions or provide informed consent (e.g., moderate to severe dementia), or\n* Enrolled in hospice, or\n* With an estimated life expectancy of \\\u003C 6 months",{"count":327,"type":21},40,[24],"Lung cancer is the second-most commonly diagnosed cancer among U.S. Veterans. Substantial advances have been made in early detection through screening and treatment. The longevity of Veterans following lung cancer diagnosis and treatment has increased. Following treatment however, many Veterans experience increased symptom burden, particularly in shortness of breath, fatigue, and fear\u002Fanxiety about lung cancer, and impairments in physical and psychosocial functioning. Rehabilitation services are needed to address these survivorship challenges. This study will evaluate multi-targeted telerehabilitation with Veterans following lung cancer treatment, with goals to reduce symptom burden, improve physical and psychosocial function, and enhance health-related quality of life. This research will also develop the career of a physician researcher to acquire expertise in rehabilitation for many Veteran survivors of lung and other cancers.",[331,28],"Lung Cancer",[333,334,335,336,337,338],"Rehabilitation","Exercise training","Mindfulness training","Survivorship","US Veterans","Telemedicine",{"date":340,"type":48},"2026-01-27",{"date":342,"type":48},"2026-01-12",{"date":344,"type":21},"2027-03-30",{"name":346,"class":347},"VA Office of Research and Development","FED",{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":271,"sex":17,"minAge":18,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":361,"conditions":362,"keywords":365,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":182},"100620856","phase-2-a-study-to-evaluate-the-effects-of-the-combination-of-gi-102-with-gib-7-on-biomarkers-of-aging-in-healthy-adults-and-cancer-survivors-100620856","NCT07363057","A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors","Phase 2a, Proof-Of-Concept, Multi-National, 8-Week, Randomized, Single-Blinded, Placebo-Controlled Trial of GI-102 in Combination With GIB-7 to Evaluate Its Effects on Biomarkers of Aging in Healthy Adults and Cancer Survivors","GIANTS-1","Key Inclusion Criteria:\n\n1. Must be aged between ≥18 and ≤80 years old at the time of informed consent.\n2. At the discretion of the Investigator, must be in a state of general health that is not severely compromised (ie, no life-threatening illness or disability).\n3. Participants with a history of cancer may be included only if they meet one of the following:\n\n   1. Participants have been disease-free for ≥2 years; OR\n   2. For those diagnosed within 2 years:\n\n      * The cancer was treated with curative intent (eg, surgery, anti-cancer agents including chemotherapy)\n      * Participants have been in remission for ≥12 months\n      * Participants are not on any active cancer treatment except maintenance therapies (eg, endocrine therapy or bisphosphonates)\n      * Participants must have received systemic anti-cancer therapies without immunotherapy for their cancers\n4. Women of childbearing potential (WOCBP; see definition in Section 5.3) must agree to use a highly effective method of contraception from 14 days prior to Visit 2 until 180 days after the last dose of study medication (GI-102 or GIB-7). Fertile men must agree to use an acceptable method of contraception from 14 days prior to Visit 2 until 90 days after the last dose of study medication (GI-102 or GIB-7).\n\nKey Exclusion Criteria:\n\n1. Severe and poorly managed chronic diseases, such as advanced cardiovascular disease, kidney failure requiring transplant or dialysis, uncontrolled diabetes, detectable malignancy (≤ 2 years), severe chronic obstructive pulmonary disease (COPD), or untreatable, terminal cancer as judged by the Investigator or history of life threatening infection (eg, meningitis).\n2. Dependent on walkers or wheelchairs; severe difficulty or inability to perform activities of daily living independently or inability to perform study measures required to test muscle function (an amputee is eligible if participants can walk without walkers or wheelchair) as judged by the Investigator.\n3. Major surgery within the past 6 months or scheduled during the study period, including severe orthopedic diseases requiring joint replacement surgery.\n4. History of substance abuse or dependency or history of recreational IV drug use over the last 5 years (by self-declaration).\n5. Female participants who are pregnant, planning to become pregnant, or breastfeeding during the study period. Participants undergoing perimenopause or the menopause transition are eligible.","80 Years",{"count":358,"type":21},15,[360],"PHASE2","This Phase 2a clinical study (GIANTS-1) aims to evaluate a novel dual-combination strategy using GI-102 and GIB-7 to address key pathological features of aging, including immunosenescence (the aging of the immune system), metabolic dysfunction, and gut-brain-muscle axis dysregulation.",[28,363,364],"Healthy Participant","Elderly",[366,367,368,369,370,371],"GI-102","GIB-7","aging","immunosenescence","gut-brain-muscle axis dysregulation","metabolic dysfunction","2026-01-23",{"date":310,"type":48},{"date":375,"type":21},"2026-01",{"date":377,"type":21},"2026-10-01",{"name":379,"class":380},"GI Innovation, Inc.","INDUSTRY",{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":17,"minAge":154,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":22,"phases":391,"briefSummary":392,"conditions":393,"keywords":394,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":56},"100575198","emdr-treatment-of-conditioned-nausea-and-vomiting-in-cancer-survivors-100575198","NCT06769165","EMDR Treatment of Conditioned Nausea and Vomiting in Cancer Survivors","EMDR Treatment of Conditioned Nausea and Vomiting in Cancer Survivors - a Pilot Study","EMESIS","Inclusion Criteria:\n\n* Previously pathologically confirmed diagnosis of cancer\n* Previously treated with systemic cancer therapy\n* Persistent complaints (more than 2 months) of conditioned nausea and\u002For vomiting\n* Able to understand spoken and written Dutch\n* 18 years or older\n\nExclusion Criteria:\n\n* Ongoing psychiatric treatment\n* EMDR therapy contraindications (dissociative disorders, personality disorders or severe somatic disorders (e.g. cardiac arrhythmias))\n* Complex type 2 trauma\n* Known with recent conditions \u002F non-anti-cancer medication which can elicit nausea (e.g. pregnancy or alcohol abuses)",{"count":390,"type":21},20,[24],"To explore the effectiveness of EMDR therapy treatment in reducing symptoms of chemotherapy-induced conditioned nausea and vomiting in (former) patients with cancer.",[28],[395,396,397],"EMDR","Nausea","Vomiting","2025-12-04",{"date":400,"type":48},"2025-12-11",{"date":402,"type":48},"2025-07-02",{"date":404,"type":21},"2026-08-01",{"name":406,"class":55},"University Medical Center Groningen",{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":17,"minAge":415,"maxAge":155,"enrollmentInfo":416,"targetDuration":4,"studyType":22,"phases":417,"briefSummary":418,"conditions":419,"keywords":424,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":437,"locationsCount":439},"100454196","phase-2-exercise-training-and-nr-supplementation-trial-to-improve-fitness-in-aya-hct-survivors-100454196","NCT05194397","Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors","Intensive Tailored Exercise Training With NAD+ Precursor Supplementation to Improve Muscle Mass and Fitness in Adolescent and Young Adult Hematopoietic Cell Transplant Survivors","IAMFIT","Inclusion Criteria:\n\n1. Males and females, ages 10-30 years at enrollment\n2. Able to understand and speak English\n3. Diagnosis of leukemia (myeloid, lymphoid), aplastic anemia, bone marrow failure syndrome, or myelodysplastic syndrome requiring allogeneic HCT\n4. 6-48 months from allogeneic HCT\n5. Females must have a negative urine\u002Fserum pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study.\n6. Subject's informed consent or parental\u002Fguardian permission (informed consent) and if appropriate, child assent\n7. Minimum weight of 24 kg\n\nExclusion Criteria:\n\n1. Known sensitivity to NR\n2. Concurrent use of any medications, including statins, likely to increase risk of NR toxicity\n3. Active malignancy, investigational agent(s) within 4 wks, or supraphysiological glucocorticoids at the baseline visit\n4. Currently meeting public health exercise guidelines\n5. Use of NAD+ precursors (supra-physiologic) within 4 weeks\n6. Hemoglobin \\\u003C 10 g\u002FdL\n7. Platelets \\\u003C 50K\n8. Diabetes Mellitus requiring insulin or insulin secretagogue\n9. HbA1C ≥ 8% or fasting glucose \\> 125 mg\u002FdL; However if the participant is diabetic, both fasting glucose level and HbA1C must meet the criteria to be deemed eligible.\n10. Kidney disease (eGFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2)\n11. Liver disease Alanine aminotransferase (ALT)\u002FAspartate aminotransferase (AST) (ALT\u002FAST \\> 3 x ULN)\n12. Limitations in physical function preventing exercise testing\u002Ftraining\n13. Unstable angina or history of acute myocardial infarction (\\\u003C5 days of planned study procedures)\n14. Recurrent syncope\n15. Symptomatic severe aortic stenosis\n16. Uncontrolled arrhythmia causing symptoms\n17. Pulmonary embolus \\\u003C3 months of study procedures\n18. Thrombosis of lower extremities\n19. Symptomatic moderate or severe persistent asthma based on Forced Expiratory Volume (FEV) from pre-HCT pulmonary function testing\n20. Room air desaturation at rest ≤85%\n21. Females: Pregnant or planning pregnancy\n22. Non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (e.g. infection, renal failure, thyrotoxicosis, \\>moderate Graft versus host disease (GVHD) resulting in physical or functional impairment)\n23. Parents\u002Fguardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.\n24. For MRI procedure: Contraindications to MRI. Individuals will be screened to ensure they can safely complete the MRI. \\*participants who cannot complete the MRI will not be excluded from participation in the remainder of the study procedures if they meet those inclusion and exclusion criteria.\n25. Current weight precludes safe completion of study procedures","10 Years",{"count":157,"type":21},[360],"This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors.\n\nThe primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 weeks. Key secondary outcomes are the change in muscle strength (ankle plantarflexion) from baseline to 16 weeks, the change in grip strength from baseline to 16 weeks, the change in lower extremity muscle mass from baseline to 16 weeks, the change in muscle OXPHOS capacity from baseline to 16 weeks, and the change in aerobic capacity (VO2 max) from baseline to 16 weeks.",[420,28,421,422,423],"Lymphoblastic Leukemia","Aplastic Anemia","Myelodysplastic Syndromes","Myeloid Leukemia",[425,426,427,428,429,430,28,431],"Sarcopenia","NAD+","Exercise Intervention","OXPHOS Capacity","VO2 Max","Adolescent young adults","Hematopoietic Stem Cell Transplantation (HCT)","2025-12-02",{"date":398,"type":48},{"date":435,"type":48},"2023-02-23",{"date":47,"type":21},{"name":438,"class":55},"Children's Hospital of Philadelphia",3,{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":22,"phases":449,"briefSummary":450,"conditions":451,"keywords":452,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":56},"100519671","internet-delivered-psychological-treatment-for-cancer-survivors-100519671","NCT06046586","Internet-Delivered Psychological Treatment for Cancer Survivors","Randomized Factorial Trial of Internet-Delivered Psychological Treatment for Cancer Survivors With Clinically Significant Psychiatric Symptoms","IN-FACT-1","Inclusion Criteria:\n\n* Cancer survivor at least 0.5 years after main therapy\n* Clinically significant anxiety or depression (Patient Health Questionnaire 9 \\[PHQ-9\\]≥10, or Generalized Anxiety Disorder 7 \\[GAD-7\\]≥8, or 9-item Fear of Cancer Recurrence Inventory \\[FCRI-9\\]≥16)\n* At least 18 years old\n* Resident of Region Stockholms, Västra Götalandsregionen, or Region Skåne, Sweden (listed and de facto)\n* Sufficient technical knowledge and knowledge of the Swedish language to take part in a text-based online treatment\n* Continuous access to an electronic device that can be used to access the study web platform\n\nExclusion Criteria:\n\n* Recurrent thoughts of suicide, as based on clinical judgement aided by the structured interview and the self-report version of the Montgomery-Åsberg Depression Rating Scale (MADRS-S) item 9\n* Severe medical condition (e.g., very poor prognosis, stage IV cancer), severe psychiatric disorder (e.g., psychotic disorder, bipolar disorder, or severely debilitating substance use disorder, severe depression), or medical treatment (e.g., chemotherapy, immunotherapy, radiotherapy) that makes the treatment unfeasible\n* Other ongoing psychological treatment\n* Continuous psychotropic medication not stable for the past 4 weeks, or not expected to remain stable during the treatment period\n* Planned absence for more than one week of the intended treatment period\n* No complete the pre-treatment assessment",{"count":250,"type":21},[24],"Negative psychological effects of cancer are common, but cancer survivors are rarely offered structured psychological treatment. Internet-delivered treatments have shown some promise, but specific treatment components have not been empirically evaluated which means that it is not clear which therapies that should be prioritized. In this randomized factorial trial at Karolinska Institutet, Stockholm, Sweden, 400 cancer survivors with psychiatric symptoms are enrolled in variations on a 10-week therapist-guided online psychological treatment intended to address the negative psychological long-term effects of cancer. The aim is to determine the contribution of treatment components to the overall effect.",[28,201,202],[453,454,455],"psycho-oncology","randomized factorial trial","Internet-delivered cognitive behavior therapy","2025-11-17",{"date":458,"type":48},"2025-11-21",{"date":460,"type":48},"2025-04-10",{"date":462,"type":21},"2031-12-31",{"name":464,"class":55},"Karolinska Institutet",{"id":466,"slug":467,"hasResults":11,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":22,"phases":475,"briefSummary":476,"conditions":477,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":56},"100343387","capable-crossfit-and-physical-activity-a-better-life-experience-100343387","NCT03750981","C.A.P.A.B.L.E. (CrossFit® and Physical Activity: A Better Life Experience)","Does High-Intensity Functional Training Improve Patient Movement and Quality of Life? A Study of CrossFit® in Cancer Survivors","CAPABLE","Inclusion Criteria:\n\n* Aged 18 years or older at time of program recruitment\n* Diagnosed with any cancer\n* Cleared from their physician to participate in the program (We assume that most patients will have completed treatment, however if a patient is currently under treatment, this should be their oncologist. If the patient is not currently undergoing treatment, this could be primary care physician or oncologist).\n* Available transportation to and from the facility on session days\n\nExclusion Criteria\n\n* Widely metastatic cancers to the brain or bone may be excluded.\n* Patients using mobility assistance devices may be excluded. Exclusionary criteria will be reviewed on a case-by-case basis and patients with these limitations may be included with approval from Dr. Beebe-Dimmer and the referring physician.",{"count":474,"type":21},500,[24],"This study will introduce cancer survivors to cross-training with the expectation that the program proposed will ultimately result in superior improvements in functional performance, body composition and quality of life compared with the current American Cancer Society (ACS) guidelines for cancer survivors.",[28],"2025-11-04",{"date":480,"type":48},"2025-11-06",{"date":482,"type":48},"2018-11-12",{"date":484,"type":21},"2028-11-30",{"name":486,"class":55},"Barbara Ann Karmanos Cancer Institute",{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":496,"phases":4,"briefSummary":497,"conditions":498,"keywords":499,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":56},"100592496","perspectives-of-italian-employers-regarding-the-return-to-work-process-of-employees-who-received-a-cancer-diagnosis-a-qualitative-study-100592496","NCT06994182","Perspectives of Italian Employers Regarding the Return to Work Process of Employees Who Received a Cancer Diagnosis: a Qualitative Study","employers_2024","Inclusion Criteria:\n\n1. employers\\* of a company\n2. being directly involved in managing the RTW process of at least one employee with cancer diagnosis in the last 5 years.\n\n   * An employer can be the specific person who represents the company where the employee was working at the time of cancer diagnosis or a person who supported the employee during the sickness absence and the RTW process (e.g., line manager, human resource manager).\n\nExclusion Criteria:\n\n* none",{"count":495,"type":21},30,"OBSERVATIONAL","European Cancer Mission calls attention to the return to work (RTW) of cancer survivors (CSs), as one of the pivotal issues of the cancer continuum that need to be addressed through proper and prompt actions and recommendations. Employers are important stakeholders, as they can provide emotional and practical support, sustain communication during the entire process, and guarantee a gradual work reintegration. In Italy there is lack of knowledge regarding this topic. Thus, further exploration of Italian employers' perspectives on the RTW of employees with cancer should be performed to comprehend their unknown experiences.\n\nThe aim is to explore the perspectives of employers who dealt with the RTW process of employees who received a cancer diagnosis through a qualitative research design.",[28],[28,500,501,502],"Return to work","Employers","Qualitative Research","2025-08-28",{"date":505,"type":48},"2025-08-29",{"date":507,"type":48},"2025-04-01",{"date":509,"type":21},"2027-02",{"name":511,"class":512},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",{"id":514,"slug":515,"hasResults":11,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":22,"phases":521,"briefSummary":522,"conditions":523,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":56},"100585919","addressing-social-determinants-of-health-among-metro-detroit-cancer-survivors-100585919","NCT06908629","Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors","Addressing Social Determinants of Health (SDOH) Among Metro Detroit Cancer Survivors: A Pilot Feasibility Study (The Resource Ready Study)","Inclusion Criteria:\n\n* 18 years or older\n* past or current cancer diagnosis\n* reside in metropolitan Detroit (Wayne, Oakland, Macomb counties)\n* English proficient\n* Actively receiving care through one of Karmano's Cancer Institute's outpatient clinics OR post treatment survivors in the Detroit Research on Cancer Survivors (ROCS) longitudinal cohort study who have reported past food insecurity and agreed to be contacted for further research\n\nExclusion Criteria:\n\n* none",{"count":191,"type":21},[24],"The goal of this screening study is to determine the feasibility of completing a social needs screening tool in participants who have a past or current cancer diagnosis and reside in Metro Detroit, Michigan. Main questions to answer are:\n\n* Can we have a completion rate of at least 80% of participants filling out the screening tool?\n* Can we determine procedures for patient referrals based on social needs\n* Can we implement brief interventions based on food access and digital inclusion (ensuring everyone has access to the digital technologies they need to participate in society)",[524,28,525,526,527],"Cancer","Gastrointestinal Cancers","Neuroendocrine Tumors","Multiple Myeloma, Neoplasms","2025-08-25",{"date":530,"type":48},"2025-08-26",{"date":532,"type":48},"2024-09-03",{"date":534,"type":21},"2027-05",{"name":486,"class":55},{"id":537,"slug":538,"hasResults":11,"nctId":539,"briefTitle":540,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":22,"phases":545,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":553,"leadSponsor":555,"locationsCount":56},"100581050","chrono-behavioral-therapy-for-chronic-fatigue-in-cancer-100581050","NCT06845267","Chrono-behavioral Therapy for Chronic Fatigue in Cancer","ChronoBT","Inclusion Criteria:\n\n1. prostate or female breast cancer survivors\n2. completed local and\u002For adjuvant cancer therapy (with the exception of hormonal therapy) ≥ 1 year previously\n3. ≥18 years of age\n4. able to speak and read Danish\n5. experiencing CRF (score ≤36 on FACT-F)\n\nExclusion Criteria:\n\n1. use of light therapy in the last year\n2. confounding underlying medical\u002Fpsychiatric disorders or use of medications associated with fatigue (e.g., a central nervous system cancer, untreated hypothyroidism, anemia, chronic fatigue syndrome, insomnia, major depression)\n3. non-cancer related factor likely to be a driver of fatigue (e.g., shift work, pregnancy, recent travel across time zones)\n4. recurrence of cancer or new cancer\n5. physical or psychological conditions that could prevent participation in intervention components\n6. use of photosensitizing medications",{"count":544,"type":21},200,[24],"Cancer-related fatigue (CRF) is a severe and persistent side effect of cancer and its treatment, affecting up to 40% of patients and significantly reducing quality of life. Recent research suggests that circadian rhythm disruption has been implicated as a possible related pathophysiological mechanism underlying CRF. Circadian rhythms are 24-hour cycles regulating physiology and behavior through environmental cues called \"zeitgebers.\" Strengthening these cues-such as light exposure, physical activity, and eating-may help reduce CRF.\n\nThis project will develop and test the optimal combination a home-based, low-burden chrono-behavioral therapy (ChronoBT) targeting these zeitgebers.",[548,28],"Chronic Fatigue","2025-03-13",{"date":551,"type":48},"2025-03-14",{"date":507,"type":21},{"date":554,"type":21},"2027-11-01",{"name":556,"class":55},"Aarhus University Hospital",{"id":558,"slug":559,"hasResults":11,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":565,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":182},"100490571","longitudinal-neurocognitive-psychosocial-and-health-related-quality-of-life-assessment-in-advanced-cancer-survivors-treated-with-immunotherapy-and-the-efficacy-of-integrative-neurocognitive-remediation-therapy-100490571","NCT05667857","Longitudinal Neurocognitive, Psychosocial and Health-related Quality of Life Assessment in Advanced Cancer Survivors Treated With Immunotherapy and the Efficacy of Integrative Neurocognitive Remediation Therapy","CognIT","Inclusion Criteria:\n\n1. Non-intervention group:\n\n   * Provision of written informed consent\n   * Diagnosed with advanced cancer of any type\n   * Initiated immunotherapy (Anti-PD1, Anti-PDL1, CTLA-4, …) at least one year ago\n   * Have a confirmed normalization on whole-body 18F-FDG PET\n   * English, Dutch or French-speaking\n2. Integrative neurocognitive remediation therapy group:\n\n   * Provision of written informed consent\n   * Objective cognitive impairment and\u002For subjective cognitive complaints\n   * Confirmed normalization on whole-body 18F-FDG PET for patients (cohort 1)\n   * Disease-free (cohort 2) or no active disease for patients with CNS tumors (cohort 3)\n   * Having received a cancer therapy of any kind\n   * Having ended cancer treatment (immunotherapy, chemotherapy, radiotherapy, surgery, …) with an exception of ongoing adjuvant hormone therapy\n   * Dutch or French speaking\n\nExclusion Criteria:\n\n* severe co-morbid non cancer-related psychiatric disorders such as psychosis, obsessive compulsive disorders, eating disorders etc., patients with cognitive impairment related to dementia, and patients that are physically or mentally not able to fill in the questionnaires",{"count":20,"type":21},[24],"Since 2010, the field of immunotherapy has grown substantially, leading to a growing population of long-term cancer survivors treated with immunotherapy. Since cancer survivorship in immunotherapy is an emerging field, to date not much is known about psychosocial and neurocognitive survivorship-related issues in advanced cancer survivors treated with immunotherapy. Preliminary findings indicated significant psychosocial and cognitive problems in survivors of advanced melanoma persist after treatment with immunotherapy. The objective for this project is twofold. First, the investigators want to longitudinally identify survival-related problems in survivors of advanced cancer treated with immunotherapy. The second goal is to identify the efficacy of an Integrative Neuro-Cognitive Remediation Therapy (INCRT) program. The investigators will focus on the following outcomes: (1) Psychosocial consequences, such as emotional complaints, fatigue, fear of recurrence, (2) neurocognitive functioning, and (3) health-related quality of life. The INCRT combines personalized computerized cognitive training and neurocognitive strategy training, with group sessions of exercise, mindfulness, Acceptance and Commitment Therapy, and cognitive behavioral therapy.\n\nWe will have three cohorts:\n\n* Cohort 1: advanced cancer survivors treated with immunotherapy\n* Cohort 2: cancer survivors treated with cancer therapy of any kind (excluded immunotherapy), and who have subjective complaints and\u002For objective cognitive impairment\n* Cohort 3: cancer survivors of a central nervous system (CNS) tumor, who do not have active disease in the CNS, and who have subjective complaints and\u002For objective cognitive impairment\n\nIn the first part of the study, survival-related problems will be evaluated in cohort 1, in a longitudinal manner by means of a semi-structured interview at baseline, various questionnaires and a computerized neuropsychological test battery.\n\nIn the second part of the study, patients of cohort 1, 2 and 3 with subjective or objective cognitive dysfunction can follow the INCRT program. The efficacy of the INCRT is evaluated through a pre-INCRT and post-INCRT evaluation. This evaluation consist of several questionnaires and neuropsychological tests. Long-term efficacy will be evaluated by a follow-up evaluation six months after completion of the INCRT program.",[568,569,73,570,571,28,572,573,196],"Cognitive Remediation","Neuropsychology","Psycho-Oncology","Cognitive Behavioral Therapy","Immunotherapy","Cognitive Dysfunction","2025-01-16",{"date":576,"type":48},"2025-01-20",{"date":578,"type":48},"2022-07-13",{"date":580,"type":21},"2033-12",{"name":582,"class":55},"Universitair Ziekenhuis Brussel",{"id":584,"slug":585,"hasResults":11,"nctId":586,"briefTitle":587,"officialTitle":587,"acronym":4,"eligibilityCriteria":588,"healthyVolunteers":11,"sex":17,"minAge":589,"maxAge":590,"enrollmentInfo":591,"targetDuration":4,"studyType":22,"phases":593,"briefSummary":594,"conditions":595,"keywords":596,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":56},"100451115","multidisciplinary-rehabilitation-of-children-and-adolescents-after-acute-cancer-treatment-100451115","NCT05154305","Multidisciplinary Rehabilitation of Children and Adolescents After Acute Cancer Treatment","Inclusion Criteria:\n\n* between 6 months and 8 years post acute cancer treatment\n* off medical treatment\n* all possible cancer diagnosis, except for brain tumors and sarcomas\n\nExclusion Criteria:\n\n* not able to participate for 3 consecutive weeks\n* not able to perform a maximal cardiopulmonary exercise test\n* unwilling to cooperate\n* relapse","8 Years","21 Years",{"count":592,"type":21},60,[24],"Recent numbers display a 85% survival-rate in children after a very harmful disease such as cancer. However, the survivors still experience mild to severe side effects of the primary disease or treatment.\n\nA long time follow-up in the University Hospital of Ghent in children with cancer displays important long term side effects such as: reduced muscle strength; reduced endurance capacity; reduced exercise tolerance; fatigue; disturbed body composition with increased risk for obesity and\u002For diabetes and osteoporosis; and neuropathic damage and myopathy. These physical complaints have a significant impact on the activities and participation in daily living.\n\nThe purpose of this interventional study is to create a rehabilitation program for children after acute cancer treatment. The goal is to minimalize the previous described long term side effects of the disease. The current study should allow us to determine the effects of the intervention at the level of functioning, activities and participation. In addition, we account for the environment and personal factors as described by the International Classification of Functioning, disability and health (ICF-criteria).\n\nThe study population consists of children between 8 and 11 years and adolescents of 12 to 21 years old. All participants receive a multidisciplinary treatment for 4 months, guided by a team which includes: oncologist, rehabilitation doctor, physical therapist, dietitian, psychologist, and occupational therapist.\n\nAt the beginning of the multidisciplinary program, the participants receive psychoeducation, diet advice, tips for participation, fatigue, and psychological well-being. In general, the rehabilitation program focusses on reintegration at school and leisure activity.\n\nAfter the first assessment, an individually adjusted physical program consisting of strength and endurance training will be made. This physical program will be executed 3 times a week, 2 times guided by a physical therapist at the University Hospital or at a private practice, and ones a week by themselves at home recorded by an activity tracker. Follow-up is foreseen on monthly basis.\n\nParticipants will undergo assessment 3 times: 1) baseline (T0); 2) after 4 months treatment (T1); 3) after 1 year follow-up (T2).\n\nThe purpose of this program is to encourage patients at risk for increasing their healthy habits, exercise and participation in order to decrease long-term (side) effects.",[28,333,74],[597,598,599],"Multidisciplinary Rehabilitation","Cohort study","Childhood and adolescence","2023-12-11",{"date":602,"type":48},"2023-12-12",{"date":604,"type":48},"2019-04-02",{"date":606,"type":21},"2026-12-31",{"name":608,"class":55},"University Hospital, Ghent"]